Incyte (INCY) and MorphoSys (MOR) Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab in Combination with Lenalidomide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 111.36 -1.43 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $112.79 | 52 Week High | $118.49 | |||
| Open | $114.05 | 52 Week Low | $55.00 | |||
| Day High | $114.05 | P/E | N/A | |||
| Day Low | $111.26 | EPS | $-0.56 | |||
| Volume | 1,478,547 | |||||
| Morgan Stanley Capital Protected Notes for S&P 500 Index (NASDAQ: MOR) | Delayed: 18.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.96 | 52 Week High | $13.71 | |||
| Open | $18.96 | 52 Week Low | $9.64 | |||
| Day High | $18.96 | P/E | N/A | |||
| Day Low | $18.96 | EPS | $0.00 | |||
| Volume | 1,015,965 | |||||
